Jazz talk­ing with Japan reg­u­la­tors about an­ti-seizure med Epid­i­olex af­ter tri­al set­back

Jazz Phar­ma­ceu­ti­cals’ oral cannabid­i­ol drug Epid­i­olex has dis­ap­point­ed in a late-phase test in Japan­ese chil­dren with seizures, but the com­pa­ny is talk­ing to reg­u­la­tors there …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER